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Abstract
Background: In the post genome era, a major goal of biology is the identification of specific roles for individual genes. We
report a new genomic tool for gene characterization, the UCLA Gene Expression Tool (UGET).
Results: Celsius, the largest co-normalized microarray dataset of Affymetrix based gene expression, was used to calculate
the correlation between all possible gene pairs on all platforms, and generate stored indexes in a web searchable format.
The size of Celsius makes UGET a powerful gene characterization tool. Using a small seed list of known cartilage-selective
genes, UGET extended the list of known genes by identifying 32 new highly cartilage-selective genes. Of these, 7 of 10
tested were validated by qPCR including the novel cartilage-specific genes SDK2 and FLJ41170. In addition, we
retrospectively tested UGET and other gene expression based prioritization tools to identify disease-causing genes within
known linkage intervals. We first demonstrated this utility with UGET using genetically heterogeneous disorders such as
Joubert syndrome, microcephaly, neuropsychiatric disorders and type 2 limb girdle muscular dystrophy (LGMD2) and then
compared UGET to other gene expression based prioritization programs which use small but discrete and well annotated
datasets. Finally, we observed a significantly higher gene correlation shared between genes in disease networks associated
with similar complex or Mendelian disorders.
Discussion: UGET is an invaluable resource for a geneticist that permits the rapid inclusion of expression criteria from one to
hundreds of genes in genomic intervals linked to disease. By using thousands of arrays UGET annotates and prioritizes
genes better than other tools especially with rare tissue disorders or complex multi-tissue biological processes. This
information can be critical in prioritization of candidate genes for sequence analysis.
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Introduction
The completion of the human genome, elucidation of most
protein coding genes, and development of new tools for the
assessment of genomic variation and regulation, have greatly
facilitated our ability to identify specific genes and gene variants
involved in diverse human traits. As information accumulates,
there is substantial promise that advances in biological under-
standing will come through integrative approaches that combine
genomic data acquired from many sources [1,2,3,4]. One of the
largest sources of information is derived from genome-wide gene
expression data made possible through academic and commercial
efforts [5,6].
Integrating whole genome linkage data with whole genome
expression data may help annotate and prioritize genes for
mutation analysis in disease linkage or genome wide association
study intervals [7,8]. Unlike information based approaches for
prioritizing genes in intervals such as peer reviewed literature
and Gene Ontology (e.g. Prospector [9], GeneWanderer [10],
SUSPECTS [11], PosMed [12], GeneSniffer [13], etc.), using
gene expression data may rank all the genes in an interval even
those with little characterization (e.g. novel genes). Current tools
(GeneDistiller [14] and Endeavor [15], ToppGene Suite [16]),
which incorporate whole gene expression data all use the well
annotated but limited discrete datasets like the well known Gene
Expression Atlas dataset from Novartis which includes a genome
wide expression survey of 40 normal tissues [17]. Although the
utility of gene-gene co-expression patterns to aggregate genes of
similar function has been demonstrated [18,19,20,21,22,23],
individual microarray studies frequently suffer from the lack of
statistical power because of the relatively small numbers of samples
observed relative to the number of genes measured [24] or the
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biological states in one experiment. Thus, efforts at establishing
larger aggregates of data for meta-analysis have been pursued. For
instance, a large collection of cancer related microarray studies has
been organized at Oncomine Research [25], which has led to
novel gene discoveries not robustly identified in the individual
datasets [26,27]. Additionally, Genesapiens has pooled the largest
group of consistently well-annotated diverse microarray data in the
public domain. It contains both normal and disease tissue datasets
and can be queried for gene expression or gene-gene co-expression
networks that can be presented in graphical format. Though the
effort to annotate 17,330 human genes across 9,783 different
samples collected from the public domain is powerful, it remains
an incomplete dataset with many tissues, developmental states and
genes not present in the database. Other large gene expression
databases like Genelogic’s gene expression database may be more
robust but are unavailable to the public [28].
In general, the common wisdom within the genomics
community is that annotation information is key to the reuse of
these data [29,30,31]. While experimental annotation provides
additional power in data analysis, we believe that queries using
only small focused annotated datasets may be limiting. Therefore,
in exchange for complete absence of metadata we have created a
robust gene-gene co-expression network which we demonstrate
can outperform more focused, but smaller scale, experiments in
many cases. We constructed this network using filtered and co-
normalized data from Celsius, the largest data warehouse of
Affymetrix microarray data [32]. Celsius has accumulated more
than 150,000 co-normalized microarrays across the various
Affymetrix array designs, so is among the most powerful resources
for expression analysis. As an example of the scale, as of August
2008 more than 12,000 U133_2.0 arrays were available, which is
approximately four times larger than Genesapiens.
Here we describe the creation of a generic, web accessible tool
that we call UGET (UCLA Gene Expression Tool; http://
genome.ucla.edu/projects/UGET) that taps directly into the vast
amount of data within Celsius. In brief, we measure the
correlation of all genes with all genes within a given array
platform and provide a rapid search tool to retrieve signals of
interest. Three general examples of the use of this tool are
presented. First, UGET is used to identify a series of genes with
cartilage-selective expression, which are excellent candidates for
skeletal dysplasia mutation bearing genes extending previous work
[33]. This same approach can be implemented to identify gene
lists relevant to other disease/traits/tissue functions. Second, we
apply the large-scale human gene-gene correlation analysis to a
retrospective analysis of prioritization of individual genes for
mutation analysis within various linkage regions in five different
disease models: muscular dystrophy, microcephaly, Joubert
Syndrome, skeletal dysplasia, and neuropsychiatric disorders. We
compare these results to results obtained by other tools which also
use whole genome gene expression to prioritize genes. While we
demonstrate the successful use of the tool for humans, we note
that the tool includes data for 14 species on 41 different array
platforms.
Results
Our aim was to create a tool that permits scientists to explore
the data available within Celsius and demonstrate the utility of
these data in human disease gene identification as a general proxy
of the information within the dataset. To do this we created data
matrices of gene-gene correlations and demonstrate two methods
to simply mine the matrix of correlation coefficients. For these
demonstrations we use the Affymetrix HG-U133_Plus_2 array
design. We use in these analyses probeset ? gene symbol
mappings available from NetAffx [34] and probeset ? genome
alignments available from the UCSC Genome Browser [35] and
exclude all other information about the microarray experiments
that were performed. In the prediction of gene function we utilized
human-reviewed Gene Ontology (GO) Biological Process (BP)
codes, as available from Bioconductor [36,37]. In all cases,
metadata about the biological samples, sample treatments, and
other conditions of the original experiments were omitted from
our analyses in order to demonstrate the power of the approach in
the absence of annotation data.
The first step of the array processing demands some level of
removal of poorly performing arrays, as systematic high and low
signals that are highly correlated would dominate the results. As an
example of this filtering process, from 12,826 arrays available
within Celsius and performed on the HG-U133_Plus_2 arrays 711
arrays were removed as having signal that was 3 standard
deviations below the mean of the whole group and 15 were
removed for having signal 3 standard deviations above the mean
of the whole group. In addition, 464 arrays were removed as the
correlations between 62 probesets, which are intended to be
measuring the same doped-in transcript, had high variability
(Figure 1). Thus, 11,636 arrays remained for analyses, which were
processed for probeset intensities using RMA [38] as implemented
within Celsius as previously described [32]. From these 11,636
arrays we calculated the Pearson correlation coefficient for every
pair of 54,675 probesets yielding a 54,675654,675 correlation
matrix, denoted C’’. These data are stored online and are
accessible in bulk (http://genome.ucla.edu/u/projects/UGET/
matrices) or are searchable through a web application called
UGET. Each array platform was processed in a similar fashion.
The July 2008 freeze is used for all of the reported analyses here.
Figure 1. Regressions of control probesets reveal aberrant
arrays. Multiple regressions were performed for all 62 HG-U133_Plus_2
control probesets. Arrays (x-axis) are plotted versus the fraction of
observations with regression residual w3s (y-axis). A dashed horizontal
line indicates a cutoff above which arrays are omitted from analysis.
doi:10.1371/journal.pone.0008491.g001
UGET
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We first attempted to determine if the agglomerated data and
gene-gene correlation matrix could be applied to a well studied
and useful effort to identify genes with cartilage selective
expression, and identify novel genes not obvious in more directed
prior experimentation. Funari and colleagues compared gene
expression in developing cartilage with a set of non-cartilage
tissues to identify genes with a pattern of high expression in
cartilage and little or no expression in non-cartilage tissues [33].
These data have already been used for successful candidate gene
identification for skeletal dysplasias and facilitated identification of
genes causing two skeletal dysplasia phenotypes [7,8]. To illustrate
the use of UGET in this way, we attempted to expand the gene list
of a subset of cartilage-selective genes [23,33]. The original list of
161 genes was identified on three platforms and was enriched for
genes that when mutated lead to skeletal anomalies. A subset of
these genes (52 genes; 58 probesets) identified on the U133A
platform was selected to assess the utility and validity of UGET.
Gene-gene correlation data from the 58 probesets were median
centered in column and row to easily visualize differences, then
subjected to 2-way hierarchical clustering (Figure 2). Within the
11,636 arrays, genes from the original cartilage-selective list
clustered into three distinct groups, suggesting three different
patterns of gene expression [33]. Interestingly, one cluster of genes
(highlighted in blue in Figure 2) contains most of the well known
cartilage-specific proteins and mutations in 14/18 genes in this
cluster can cause skeletal anomalies in humans or mice. Of the
4/18 genes (LIF, CSPG4, EDIL3, and MATN4) not associated with
skeletal anomalies, two have not been characterized in mouse
models. They also contain the strongest correlations and therefore
most homogenous expression pattern. Therefore, genes with the
highest correlation at the center of this node were then used as a
primary seed to search for additional genes with the same
expression pattern. This first step in the assembly of the gene
expression patterns with Celsius is to identify the probesets with
the highest correlations of this seed list of known, related genes
(referred to as a profile). Next, the mean correlation coefficient to
the profile ( r r) was calculated for each gene across the genome that
was present on the array. Finally, we rank-ordered the set of all
probesets and the set of the initially selected probesets by  r r.
Using the default setting, the one hundred genes with the
highest correlation to the seed profile were returned (Table S1). 44
of these genes (56 probesets) were identified in a previous
supervised analysis in Funari, 2007 et. al., which used well-
annotated arrays. These genes are indicated by the column ‘‘CV
and fold change’’ in the Table S1. These results suggest that even
without metadata, the UGET analysis identifies a comparable
gene list. In fact, some of the differences among the lists may be
attributed to the stringent filtering in the supervised analysis, the
emphasis of the statistical approaches, the use of different
platforms, and the limited number of tissues and arrays surveyed
in the classical preliminary study. To illustrate this, when our list
was compared to the supervised 2-class SAM analysis performed
on the similar U133 2.0 platform, 76 probesets (59 genes) were
identified in the top 200 ranked probesets. Assuredly, there was a
dramatic enrichment of probes for genes that have already been
associated with skeletal defects in mouse or man using the UGET
provided hyperlinks for the associated genes in Online Mendelian
Inheritance in Man (OMIM) and Mouse Genome Database
(MGD) databases [39,40]. Although only 44/100 probesets were
associated with gene targeted mouse phenotypes, 23 of these were
associated with genes that appear to be involved in normal fetal
cartilage developmental in mice. Additionally, 10 more probesets
represented genes associated with skeletal defects but have not yet
been identified as associated with fetal cartilage development (e.g.
Bone, Adult Cartilage, other Skeletal phenotypes). Most of the
probesets (54) could not be associated with a single mouse model,
illustrating at least in part how relatively uncharacterized the
cartilage genome is. It is likely that many of these and other
skeletal probesets will later be associated with genes with critical
roles in cartilage development in man and/or mice. An example of
this is the lack of an obvious cartilage development phenotype in
TRPV4 targeted mice, however gain of function mutations in
TRPV4 can cause Brachyolmia in humans [7]. Additionally,
mutations in COL9A2 cause epiphyseal dysplasia [41], yet there
is not yet a targeted mouse model for this gene. Interestingly, the
gene-gene correlations identified 32 genes not previously defined
as cartilage-selective [33] (gene rows are highlighted in Table S1).
Some of these newly identified genes are well characterized as
cartilage-selective and associated with one of a variety of forms of
skeletal dysplasia (e.g., TRPV4, COL2A1, COMP, and CO-
L9A3). In fact, although TRPV4 was not identified as cartilage-
selective in the Funari et al. 2007 effort because of its low level of
expression in cartilage, Rock and colleagues have recently
characterized TRPV4 mutations as causative of brachyolmia [7].
To further validate these genes as cartilage-selective, qPCR was
used to survey a subset for expression level in normal fetal cartilage
and seven non-cartilage tissues (Table 1). Seven genes equally
distributed in the ranked list (ca. every 10 genes) for which little
functional annotation existed were used for validation. Top ranked
and cartilage-selective ACAN was used as a positive control to
illustrate a known cartilage-selective expression pattern while no-
template reactions served to assess specificity. In brief, three of the
seven genes appear to be relatively cartilage-selective, containing
minimal if any expression in other tissues. Gross abnormal skeletal
structure, decreased body length and growth retardation were
reported in FZD9 targeted mouse (Fzd9
tm1Lex) [40], while no
functional characterization of SDK2 and FLJ41170 has yet been
performed. Importantly, all of the genes demonstrated a cartilage-
selective expression pattern, expressing on average 6.4 times more
of the transcript than any non-cartilage tissue with little if any
expression in non-cartilage tissues (,Ct=33). The strength of this
tool is realized in this example. Unlike most of the well-
characterized extracellular matrix proteins (e.g. ACAN) with high
expression in cartilage (Ct=24), this group of validated genes
represented low expression in cartilage (ca. Ct=29). The
sensitivity of this analysis underscores the power of using a large
array dataset for gene-gene correlation measures. In effect, the
scale of the data reduces the otherwise substantial requirements for
a minimum fold change filter often used to circumvent false
positive detection when using small numbers of samples.
Finally, mouse often provides a good model for many diseases
and the findings from searching the human gene-gene correlations
should be supported in the available mouse data. The mouse
orthologues of the 14 human genes used as a profile of human
cartilage were also used as a profile for mouse cartilage.
Approximately, 50 percent of the human cartilage-selective genes
(44 genes [54 probes]) were also identified in mouse as cartilage-
selective. Within this group, twenty-two genes were identified
which cause skeletal defects in mice or humans, which is a high
enrichment of skeletal dysplasia genes. In aggregate, these results
demonstrate the power of the unannotated expression data to
identify genes of similar expression pattern and role in a disease
process, which were validated in silico and in vitro.
Disease Gene Identification
Typically, a genomic region is initially linked to Mendelian
disease through the observation of regional haplotypes shared in
UGET
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8491excess within affected pedigrees, delineating a single genomic
interval to be examined for causative mutations [42,43]. These
linkage regions are commonly up to 6–15 megabases (Mb) in size,
and thus typically contain on the order of 100–300 genes, many of
which lack any meaningful characterization. This complicates the
disease gene discovery processes, and can stall progress significantly.
Often there are one to several different genes (outside a linked
interval of interest) that, when mutated, lead to an identical or
highly similar phenotype. For instance, Joubert Syndrome (JBST)
is known to map to at least 7 different loci and Limb Girdle
Muscular Dystrophy Type 2 (LGMD2) maps to at least 11 loci,
and both will likely map to more. As additional disease genes for a
given condition are identified, it is commonly observed that all the
identified genes play critical roles in a shared biological process
(BP), and when any one of the components of this process is
disrupted it leads to the dysfunctional phenotype. Given that these
genes are involved in the same BP, it is reasonable to assume that
they will be co-expressed in similar tissues/cell lines or in response
to similar exogenous treatments of cells that have been performed
and assessed on genome-wide microarrays deposited in Celsius.
Figure 2. Analysis of cartilage-selective probesets previously identified on U133A platform using two-way clustering of gene-gene
correlation data. Gene-gene correlations were identified for all cartilage-selective probesets previously identified on the U133A platform [6].
Dendrograms from two-way clustering of the median-centered correlation data suggest three distinct expression patterns. The strongest node (blue)
was selected as a cartilage profile for further expansion by seeding the UGET.
doi:10.1371/journal.pone.0008491.g002
UGET
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of expression levels among the diverse set of disease causing genes
at different locations in the genome which all cause a similar
disease when mutated. To demonstrate this we retrospectively
assess known linkage intervals by rank ordering all genes over the
linkage interval by their correlation coefficient with known disease
causing genes (or a set of genes known to participate in the critical
BP).
Our method was to assemble a list of genes G known to be
associated with the disease or critical biological process. Each gene
identifier g [ G was mapped to the corresponding list of probesets
on the HG-U133_Plus_2 array design. The list is denoted Pg, and
we denote this mapping function as Jg ðÞ . For each probeset
pg [ Pg, the genomic position was retrieved using the UCSC
Genome Browser [35]. We then retrieved a list of probesets Qg,
which aligned to the candidate interval pg, and we denote this
mapping function as Kp ðÞ . Next, for each probeset qQ
gg
[ we
calculated the mean correlation coefficient  r rg to pg using C’’, and
we denote this as L(q,C0). Finally, we rank order each gene within
the interval by the maximum correlation coefficient of probes
mapping back to gene symbol (max  r r).
We first applied our method to LGMD2, which is genetically
heterogeneous. There are 11 genes known to be mutated that lead
to LGMD2: CAPN3, TCAP, TTN, SGCA, SGCB, SCGD, SGCG,
POMT1, FKRP, TRIM32 and DYSF [44]. In order to determine if
we could highlight the known gene of interest within the
approximate linkage interval by using a profile created from the
other known LGMD2 genes, we considered a 6 Mb interval
centered at each of the 11 named genes above. All probesets
designed to measure gene expression from the U133_2.0_Plus
arrays within the 6 Mb genomic region were included for analysis.
We calculated the mean correlation coefficient  r r to the 10-gene
LGMD2 profile for each probeset within each of the 11 regions, as
we excluded any probesets targeting the gene that maps within the
selected linkage region. For instance, in the titin (TTN ) interval, all
genes except TTN were used for the gene correlation calculation.
In 55% (6/11) of the cases max  r r corresponded to the causal gene
for LGMD2. In 2 of the 11 cases the causative gene was the
second most highly correlated with the LGMD2 gene set, for three
genes (FKRP, POMT1, and DYSF) there was poor correlation with
the LGMD2 gene set. The high frequency of the correlation of the
known causative gene with the overall LGMD2 gene set is highly
significant relative to the mean number of genes (n=72) in each
6 Mb interval (p-value=1.24e-09). As an example,  r r-values
surrounding the LGMD2J locus on 2q24 for which the known
mutated gene is TTN are shown in Figure 3, which demonstrates
the strongest correlation with TTN relative to all other probesets
mapping to the 6 Mb interval. Since most of the genes involved in
LGMD2 should be expected to play a role if expressed in muscle,
the positive correlation is largely based on co-expression within
muscle tissues and thus other muscle specific genes may also be
highly correlated and within the interval. It is important to note
that the success of UGET in identifying disease genes is inversely
related to the size of the candidate interval, as larger intervals are
more likely to contain multiple genes involved in the BP of interest
which to not contribute to the disease of interest.
We applied this method to see if the tool was able to highlight
genes involved in primary microcephaly, which is clinically
diagnosed when an individual has a head circumference more
than three standard deviations below the mean with no apparent
biological or environmental cause. From a review of the Online
Inheritance of Man [39], six loci have been mapped, and four
genes identified: ASPM, CENPJ, MCPH1, CDK5RAP2 thus far.
The purpose of this test was to confirm that the methods used in
our LGMD2 trial would effectively identify genes for a completely
different and highly genetically heterogeneous phenotype, as well
Table 1. Summary of qRT-PCR amplification of cartilage-
selective genes in fetal cartilage and seven non-cartilage
tissues.
Ct
Rank Gene Cart NCart Neg Fold
4 ACAN 24 34 6 1024
23 FZD9 29 6 Unique
32 SDK2 31 7 Unique
47 SLC39A14 25 28 8
64 PDE10A 31 33 3 4
67 SUSD5 29 32 2 8
83 TWSG1 28 31 8
93 FLJ41170 31 33 4 4
Representative genes are listed in rank order of similarity to the human
cartilage selective genes used in the seeding profile. Cart: mean Ct value for
cartilage samples. NCart: Mean Ct value for the 7 non-cartilage samples. Neg:
Number of non-cartilage tissues in which amplification was not detected at 35
cycles. Where no amplification was observed the maximum Ct value (i.e. 35)
was used for calculations. Fold difference (Fold) is calculated from the
difference in cartilage and non-cartilage Ct values.
doi:10.1371/journal.pone.0008491.t001
Figure 3. Gene correlations to a list of LMGD2-associated
genes within a 6 megabase region surrounding the location of
a known associated gene. The genomic position (x-axis) of
probesets within a 6 megabase region centered at the location of
TTN, a gene known to be associated with LMGD2, is plotted versus the
Pearson correlation coefficient r (y-axis) to a list of probesets targeting
other genes known to be associated with LGMD2 (excluding TTN)
across 11636 HG-U133_Plus_2 microarrays. Solid circles: probesets
targeting TTN, |: probesets that are for genes of unknown function
and, open circles: probesets for known genes in interval.
doi:10.1371/journal.pone.0008491.g003
UGET
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gene given a much smaller profile for comparison. In 75% (3/4) of
cases the most correlated gene with the other known microcephaly
genes was correctly identified from a 6 Mb linkage region
surrounding that gene. Thus, for diseases that are genetically
heterogeneous, once a small number of the identified genes is
known, rank ordering other genes is a viable strategy.
We applied the scanning method to Joubert syndrome (JBTS),
which is a genetically heterogeneous neurodevelopmental disorder
characterized by the ‘molar tooth sign’ demonstrating hypoplasia of
the cerebellar vermis and associated with developmental delay and
various physical malformations. Eight linkage regions for Joubert
syndrome have been identified (JBTS1-JBTS8). Five of these have
had the associated gene in the region identified (JBST1=INPP5E;
JBTS3=AHI1; JBTS4=NPHP1; JBTS5=CEP290; JBTS6=
TMEM67; JBTS7=RPGRIP1L) [45,46,47,48,49,50,51,52,53,54]
while JBTS2 has so far only been linked to a 17 Mb centromeric
region of chromosome 11 [50,55,56,57], respectively. The purpose
of this third test wastoprovide anotherinstanceof reproducibilityof
results and determine if we could make a prediction as to the
identity of the genes in remaining linked regions JBTS1 and JBTS2
for which a gene has not yet been identified. We were able to
correctly prioritize 67% (4/6) of the five genes known to be
associated with JBTS as the first ranking candidate in a 6 Mb
interval surrounding each. AHI1 was ranked fourth out of 89 genes
in its 6 Mb surrounding interval, and INPP5E was the 19
th of 98
genes. Both are positively correlated with the other known genes,
but are not strongly highlighted indicating that the approach will
not always be successful. An example of a successful identification is
shown of the plot of  r r-values surrounding NPHP1 is given in
Figure 4A. We also show data from the Gene Expression Atlas [17]
for the same region in Figure 4B, demonstrating that NPHP1 could
not be identified merely by scanning this region for brain-specific or
even brain-expressed genes. Thus, similar to the increased numbers
of genes identified as cartilage-selective from the un-annotated
arrays, there are subtle gene expression signals that are possible to
identify simply from large scale data that preserve information
about the similarity of gene expression in a variety of conditions
(that are unknown to us) but remain informative for gene
characterization. We examined JBTS2, which is a centromere-
spanning 17 Mb region on chromosome 11 between markers
D11S1915 and D11S4191. The best candidate based solely on the
expression data for JBTS2 is AGBL2. However, this is a large region
and there are other highly correlated genes on both sides of the
centromere.
To assess the broader utility of UGET analysis, we examined
ten additional genes identified as contributing to neuropsychiatric
disorder within candidate genomic intervals. As autism is a widely
studied common neuropsychiatric disorder with high heritability
[58,59], we postulate the expression patterns of genes likely
contributing to autism [60] are broadly relevant neuropsychiatric
disorders due to shared biological processes (central nervous
system development and function). We thus used an autism-related
expression module to rank genes within candidate regions using
UGET (Table S1). In each case, the rank of genes within the
candidate genomic interval was highly correlated with the gene
known to contribute to the disorder, identifying the known gene as
the first or second most highly correlated gene in five out of ten
intervals (Table 2). Mean expression correlation scores for all ten
genes studied were greater than one standard deviation above the
mean for all genes, and greater than two standard deviations
above the mean for eight out of the ten genes. While this analysis is
Figure 4. Gene correlations to a list of Joubert syndrome-associated genes within a 6 megabase region surrounding the location of
an associated gene. A: The genomic position (x-axis) of probesets within a 6 megabase region centered at the location of a NPHP1, a gene known
to be associated with Joubert syndrome, is plotted versus the Pearson correlation coefficient r (y-axis) to a profile created from probesets of all other
genes known to be associated with Joubert syndrome (excluding NPHP1) across 11,636 HG-U133_Plus_2 microarrays. Solid circles: probesets
targeting NPHP1, |: probesets not designed to target a known gene, open circles: other probesets across interval for known genes. B: Probeset
positions in ascending genomic order (x-axis) versus tissue (y-axis) from the GNF Expression Atlas 2 are presented as a tissue-clustered, column-scaled
heatmap. Black=low expression, white=high expression. Black bars in the margin indicate brain tissue rows, and the column representing Joubert
syndrome-associated gene NPHP1.
doi:10.1371/journal.pone.0008491.g004
UGET
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broadly applicable candidate gene prioritization tool for complex
disorders.
Using the 10 neuropsychiatric disorder intervals and the 3
skeletal dysplasia intervals mentioned above with the seed lists
mentioned in Tables S2 and S1, respectively, we attempted to
assess the relative efficacy of UGET compared other well used
gene expression prioritization tools (GeneDistiller and Endeavour).
The known disease gene was identified as a top 5 candidate gene
in 11/13 disorders using UGET, 10/13 disorders using GeneDis-
tiller, and 5/13 disorders using Endeavor. In the skeletal disorders,
where the gene defect is in a cartilage-selective gene expressed in a
rarely characterized tissue (i.e. cartilage growth plate), UGET
outperformed these other tools.
Human Disease Network
In order to determine the generality of the approach, we
selected human disorders from a broad array of disease classes
[61]. We selected 43 examples of disorders on the basis of the
largest number of genes affiliated with each trait, while attempting
to sample both Mendelian disorders and some more complex
disorders such as hypertension. We then compared the Pearson
correlation coefficients between all genes that are associated with a
given disorder (intra-disorder correlation) to the Pearson correla-
tion coefficients between these genes with all other genes in
U133_2.0 arrays (extra-disorder correlation), and the results are
shown in Table 3. In total, 36 of 43 (84%) had detectable
enrichment in intra-disorder correlation with a p-value less than
0.05. Seven disorders had no such enrichment including
Hirschsprung disease, Charcot Marie Tooth disease, Holoprosen-
cephaly, Long QT syndrome, Spondyloepiphyseal dysplasia, and
Nephronophthisis. This would indicate that the genes responsible
for these syndromes are generally not co-expressed across diverse
tissue types. Conversely, genes, mutations in which lead to
cardiomyopathy, are very highly correlated with each other
(p=6.4610
2146) indicating that a restricted pattern of expression
is common for this group of disease genes. The strongest mean
intra-disorder correlation observed was for the genes causing
Complement Component Deficiency, Ehlers-Danlos Syndrome
and myopathy which all have mean intra-disorder correlation of
over 0.26, which are highly significant and also are consistent with
high expression in perhaps a restricted tissue or cell type. Included
in this analysis were several common and clearly genetically
complex disorders including obesity, hypertension, diabetes
mellitus, schizophrenia, rheumatoid arthritis, and asthma. In all
of these complex disorders genes that cause the disorder are
substantially more likely to be correlated with the other known
genes. This has the potential for providing important orthogonal
associative information about individual genes in complex
disorders in general, as genome wide association studies and rare
variant searches are highly prone to false positive detections. Thus,
there is strong evidence that genes that cause a given disorder are
likely to be more similarly co-expressed across diverse gene
expression experiments that UGET is detecting. To access this
Table 2. Evaluation of expression-based candidate gene prioritization tools.
Disease Gene Interval (Mb) Disorder & Evidence
Total
Genes UGET Endeavor GeneDistiller
Rank Genes Rank Genes Rank Genes
DOC2A chr16:29.5–30.2 Autism
Rare Variant [62]
3 022 272 6 12 9
SEZ6L2 chr16:29.5–30.2 Autism
Associated Variant [62]
3 052 212 6 22 9
CACNA1G chr17:20.1–46.1 Autism
Association [63]
452 14 396 129 357 24 324
DOCK4 Chr7:106.2–118.6 Autism
Association & CNV [64]
4 334 123 6 23 4
SYNJ1 chr21:30.5–46.9 Bipolar Disorder
Association [65]
1 7 61 1 3 31 1 1 52 1 1 5
CACNA1A chr19:4.9–18.2 FHM
Monogenic Sub-type [66]
3 4 12 3 0 61 2 3 08 2 3 3
NTRK3 chr15:83–96.3 MDD
Association [67]
63 1 58 15 45 4 61
ATP1A3 chr19:43.4–47.3 RDP
Monogenic Sub-type [68]
1 1 22 1 0 31 5 7 9 2 9 0
PRKCA chr17:54.9–68.4 Schizophrenia
Association & Rare Variants [69]
89 4 82 15 74 4 81
NOS1AP Chr1:156.2–161.8 Schizophrenia
Functional Common Variant [70]
110 5 88 3 78 2 66
TRPV4 chr12:107–119 ADB
IBD Linkage & Functional Evidence [7]
149 1 72 27 85 5 103
ACAN chr15:72–89.4 SEMD
IBD Linkage & Genetic Evidence [8]
2 6 91 1 7 31 1 4 84 1 2 8
Genes within 11 mapped genetic intervals for 10 neuropsychiatric and two skeletal disorders were retrospectively ranked by UGET, Genedistiller, Endeavor by gene
expression correlation to either known disease genes or genes which play important roles in an associated biological process. Grey boxes indicate that the disease gene
was ranked in the top five candidates using the tool. Abbreviations: IBD=Identity-by-decent; CNV=Copy Number Variant; FHM=Familial hemiplegic migraine;
MDD=Major Depressive Disorder; RDP=Rapid-onset dystonia Parkinsonism; ADB=Autosomal dominant brachyolmia; SEMD=Spondyloepimetaphyseal dysplasia;
ATD=Asphyxiating thoracic dystrophy; SRP=Short rib polydactyly syndrome.
doi:10.1371/journal.pone.0008491.t002
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8491Table 3. Disease genes within a classification are more strongly correlated with each other than with genes not linked to the
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Disorder Name
No. of
Genes
No. of
Probesets
Mean Intra-disorder
Correlation
Mean Extra-disorder
Correlation
Signif. of
Enrichment
Epiphyseal_dysplasia 6 10 0.196 20.005 1.9E-05
Osteoporosis 6 23 0.059 20.007 1.3E-06
Amelogenesis_imperfecta 4 9 0.070 0.018 2.6E-02
Osteopetrosis 4 10 0.087 0.011 3.1E-03
Leukemia 37 162 0.024 0.016 5.0E-12
Colon_cancer 34 88 0.029 0.015 1.3E-08
Cardiomyopathy 25 68 0.155 0.009 6.4E-146
Hypertension 12 23 0.031 20.001 5.2E-07
Long_QT_syndrome 7 13 0.019 0.012 5.6E-01
Ehlers-Danlos_syndrome 9 31 0.270 20.018 7.5E-54
Rheumatoid_arthritis 8 25 0.075 0.021 2.4E-14
Epidermolysis_bullosa 11 25 0.236 0.002 6.5E-47
Ectodermal_dysplasia 8 18 0.096 0.016 6.9E-11
Holoprosencephaly 5 4 20.008 0.015 3.9E-01
Deafness 41 96 0.016 0.008 8.8E-05
Diabetes_mellitus 27 54 0.025 0.014 3.4E-04
Hirschsprung_disease 7 14 0.010 0.002 2.5E-01
Hemolytic_anemia 10 21 0.119 0.000 2.6E-15
CCD 13 19 0.321 20.010 3.4E-35
SCID 8 18 0.242 0.018 1.5E-30
Cent. Dis. Glycosylation 13 22 0.127 0.009 7.9E-17
Porphyria 6 26 0.073 0.008 3.5E-09
Fanconi_anemia 11 27 0.188 0.021 6.4E-37
Zellweger_syndrome 11 27 0.101 0.011 6.6E-27
Bardet-Biedl_syndrome 8 16 0.137 0.007 1.1E-08
Usher_syndrome 8 15 0.048 0.018 4.7E-03
Hermansky-Pudlak_synd 7 19 0.095 0.013 7.5E-11
Muscular_dystrophy 18 39 0.157 0.008 2.1E-66
Myopathy 10 15 0.264 0.005 2.8E-13
Mental_retardation 24 50 0.043 0.017 3.9E-10
Charcot-Marie-Tooth 18 36 0.018 0.008 9.0E-02
Spinocereballar_ataxia 13 27 0.061 0.022 3.8E-04
Leigh_syndrome 12 24 0.151 0.003 8.6E-18
Obesity 21 42 0.013 0.004 8.4E-04
Retinitis_pigmentosa 30 51 0.079 0.021 1.2E-26
Cataract 15 18 0.120 0.025 3.0E-09
Schizophrenia 9 20 0.082 0.012 1.2E-06
Renal_tubular_acidosis 5 11 0.034 0.002 4.3E-02
Nephronophthisis 4 12 0.006 0.010 8.1E-01
Asthma 13 24 0.039 0.004 4.0E-10
Cent_hypoventilation_syn 5 10 0.040 0.010 1.5E-02
Brachydactyly 5 10 0.011 20.003 5.5E-02
Spondyloepiphyseal_dyspl. 5 9 0.003 0.015 5.8E-01
No. of genes: total number of genes in U133_2.0 arrays identified that are associated with a disorder name (44); No. of probesets: total number of probesets mapping to
the genes; Mean Intra-disorder Correlation: mean Pearson correlation coefficient for all disease genes; Mean Extra-disorder Correlation: mean correlation between
disease genes and all other genes in U133_2.0 arrays; Significance of Enrichment: t-test p-value comparing intra-disorder correlation with extra-disorder correlation.
doi:10.1371/journal.pone.0008491.t003
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genes linked to a given disorder has been created on the UGET
website such that an investigator can select from the human
disorder names and retrieve those genes mapping to that disorder
for input into UGET.
Discussion
We describe here the creation of a new web-accessible gene-
gene correlation resource, and demonstrate the power and utility
of a large collection of gene expression microarray data for
functional gene discovery and for prioritizing genes for mutation
analysis within linkage regions.
We first expanded a list of known cartilage-selective genes in
mouse and humans. Within this process, 7 genes (out of 10) all
with poor or little annotation were validated and demonstrate
cartilage selective expression. Two novel genes tested, SDK2 and
FLJ41170, are very selectively expressed in fetal cartilage. The
power of a large dataset is realized with this example as rare tissues
(e.g.cartilage or fetal cartilage) and many novel genes (e.g.
FLJ41170) are not present in Genesapiens. In addition, it is
remarkable that despite the relatively small number of human fetal
cartilage gene arrays in the public domain (,14 vs. 10,000 arrays),
UGET is remarkably sensitive even when it comes to genes
expressed in few tissues. Similarly, UGET can be used iteratively
by scientists to identify genes with similar expression profiles for a
variety of patterns in order to identify genes that may be involved
in specific biological processes.
By simple use of UGET, the correct retrospective identification
of the known causal genes within linkage regions for several
unrelated disease phenotypes was demonstrated in the majority of
cases. This simple application of the tool is in itself a highly
powerful strategy because there are many more linkage regions
reported than causal genes, yet there are many disease genes
identified for a similar phenotype. Thus, we can effectively
leverage current knowledge to prioritize genes within the many
known linkage intervals. From our small number of examples, our
evidence would indicate that, if there are at least a few known
disease genes to use to create a profile of interest, the highest or
second highest correlated gene will be the mutant gene at up to
80% of the loci. This approach is broadly applicable to more
heterogeneous traits such as neuropsychiatric disorders, with 50%
of previously identified genes within candidate intervals ranking
either highest or second highest correlated gene using an autism-
related expression module. A subset of genetically heterogeneous
disorders however, has no strong correlation of expression between
the multiple genes causing specific traits (for example, Hirsch-
sprung’s Disease). We note that the general process of gene
prioritization applies to the entire genome and may point to
strategies in the absence of linkage knowledge as well for rare
Mendelian disorders. Likewise, the genetic causes of highly
complex disorders such as autism or schizophrenia are certain to
be numerous, but as true disease genes are identified in these
disorders and others, gene-gene correlation analyses should be
applied to prioritize additional genes in the absence of linkage or
genome-wide association signals. We expect the tool to be
generally useful in a wide variety of human disease areas and to
expedite the gene discovery process. While there are other gene
expression prioritization tools and other prioritization approaches
(e.g. via interactome data and literature based) that are also
successful, the data suggest that UGET is a robust tool especially
when the genes and biological processes are better defined in rare
or more complex datasets. In this regard, UGET takes advantage
of the vast Celsius database which provides additional insight not
possible using smaller, more discrete, but defined annotated
datasets.
The tool is web accessible and easily searchable by scientists
seeking to identify genome-wide gene-gene correlations. Data are
returned as html lists for rapid perusal or as tab delimited text files
available for download. The power and versatility of this resource
initially surprised us and will be able to grow in power as
microarray data accumulate. One of the powers of this approach is
that the entire pipeline of methods used to assemble the
correlation matrix is completely metadata independent – only
the genomic alignment of probe sequences and the quantitative
measurements made by the microarray were used. This results in a
dataset that is very heterogeneous reflecting the diverse set of
human experiments ongoing in the community. It is composed
from microarray data generated from thousands of individual
experiments by hundreds of individual scientists, with each
experiment using different biological materials and different
hybridization conditions and protocols. We conclude that the
volume of data assembled here is sufficient and does not appear to
have systematic biases based on site of origin of the data or
differences in the method of data generation to mask true gene-
gene correlations due to differences in microarray protocols.
A variety of analyses presented here have established that rank
ordering of genes within a linkage interval using UGET is a
successful approach in many cases. Generally, UGET is highly
successful in ranking candidates when the disease gene has an
expression pattern specific to the biological process being studied.
Alternatively, genes involved in multiple biological processes (or
genes not involved in the disease BP in normal individuals) may
not rank as highly. As an example, AHI1 was ranked fourth best
candidate gene out of 89 genes when UGET was used to
retrospectively identify known Joubert Syndrome (JBST) genes.
AHI1 is expressed in both central nervous system tissue and
primitive hematopoietic cells, which diluted the strength of co-
expression correlation to other JBST genes. This demonstrates key
limitations in the application of the guilt by association approach
to disease gene identification. False negative results will occur in
such cases. This lessens the utility of UGET (and other methods
such as Endeavour and SUSPECTS) to providing a specific type of
biological insight. This limitation also leads to false positives
arising if genes within a candidate interval are specifically
expressed in the BP of interest but do not contribute to disease.
Despite these limitations, in the majority of retrospective cases
presented here (including AHI1), UGET analysis rank ordered
candidate genes such that sequentially sequencing the most highly
correlated genes would identify the known disease gene more far
efficiently than sequencing all genes within the candidate interval.
Thus, the limited scope of biological insight provided by UGET is
nonetheless highly informative for human disease gene discovery.
While we demonstrate the utility of this tool particularly for
human gene identification, the correlation matrices have been
constructed for the entire Celsius dataset and are available for
search within 14 different species across 41 different array designs.
We note that the scale available through this resource is
unprecedented and is the result of ignoring differences in
annotation approaches by scientists. In general the genomics
community has placed high value on the annotation information
such that publication policies typically require metadata to be
deposited concomitantly with assay measurements. However,
without truly representing the vast diversity of experiments
performed is daunting and not implemented yet. While annotation
is useful and in some cases necessary for some supervised analysis,
the practice of insisting on detailed metadata in the process of
making raw microarray data available may actually limit the
UGET
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strong motivation to provide annotation information on experi-
ments that do not become part of the published experiment and
thus these data will be excluded from repositories. In contrast to
the annotation-centric efforts of microarray repositories, the
Celsius database can import CEL data without annotation data
and the work shown here demonstrates the enormous potential
power of growing these data further. We recommend the
deposition of all CEL files into public repositories or directly into
Celsius to expand our ability to detect gene-gene correlations.
Materials and Methods
Data and Data Cleaning
We retrieved all RMA-processed gene expression data for the
HG-U133_Plus_2 array design (n=12,826 arrays) from the
Celsius microarray data warehouse [17,32] and denote the
S=12826 (arrays) | P~54675 (probesets) matrix as M.A
cursory examination of M revealed that there were aberrant
arrays present and that these arrays would have a negative impact
on any downstream analyses and thus needed to be removed in a
systematic manner. There appeared to be at least 3 groups of
aberrant arrays:
1. arrays with extremely high gene expression values across many
probesets.
2. arrays with extremely low gene expression values across many
probesets.
3. arrays with dissimilar expression values for two probesets
reputedly measuring the same gene.
We sought to systematically remove these arrays from the gene-
gene correlation calculations. Group 1 and 2 arrays were easiest to
identify for exclusion. We calculated the mean expression value of
all probesets for each array, then calculated the mean and
standard deviation of a 10% trimmed distribution of those means.
The trimmed means themselves had a mean of 231.1 and a
standard deviation of 21.0. There were 726 arrays with mean
expression value more than 3 standard deviations away from the
mean of trimmed means. These were primarily dim arrays
(n=711) but there were also excessively bright arrays (n=15).
These arrays were removed from further consideration, leaving
matrix M’ with 12,100 arrays and 54,675 probesets.
Group 3 arrays were slightly more difficult to find. To identify
them, we exploited the fact that, via NetAffx [34], Affymetrix
publishes a probeset ? gene symbol mapping for their array
designs. We assumed that pairs of probesets designed to target the
same gene were more likely to be linearly related than randomly
selected pairs because they were targeting the same gene, and that
these relationships could be used as a starting point to identify
inconsistent arrays.
There are 19,632 unique gene symbols from the NetAffx
HG-U133_Plus_2 gene annotation. Of these, there is a subset G
(n=10,433) for which there were two or more probesets. We
constructed G groups, each corresponding to a single gene symbol,
i.e.: g1=pg1 1,…,pg1n,…,gG=p gG 1,…, pgGn. Then, for each g [ G,
we performed a linear regression of log10(signal) for all possible
probeset pairs pgA,pgB (n=38,682). Examination of the probeset
pairs with the largest value of r2 revealed that the majority were
control probesets that targeted spike-in sequences that are added
as part of the microarray hybridization for quality control. Thus,
we concluded that using the built-in control probesets was a robust
way to identify aberrant arrays. We performed 62 multiple
regressions, allowing each control probeset to be the response
variable once. In the context of a single regression if an array’s
residual was, relative to all other arrays’ residuals, more than 3
standard deviations away from the line, we incremented a counter
for that array. After performing all 62 regressions, all arrays that
were observed more than 3 standard deviations more than 5% of
the time (n=464) were removed from further consideration,
leaving a matrix M’’ with 11,636 arrays and 54,675 probesets.
Outlier frequencies per array are shown in Figure 1.
Correlating Genes
Subsequent to filtering out aberrant arrays from out dataset, we
used the M’’ matrix to calculate C’’, a 54675 | 54675 matrix of
Pearson correlation coefficients for every pair of probesets
(Equation 1). C’’ was used in all results presented in Section 4.
C’’~cor MT’’ 
ð1Þ
Annotating Genes
For each probeset p [ P on the HG-U133_Plus_2 array design,
we retrieved and sorted in descending order r=C0p. We took r’,
the derivative of r, and used the R Bayesian Change Point bcp to
identify d, the index of the largest value of r’ that preceded a
mostly-linear portion of the curve. The subset of probesets where
rwd were defined as Q, and used as input to the hyperGTest
function of the GOstats package of Bioconductor [36] to test for
enrichment of Gene Ontology (GO) Biological Process (BP)
annotations in a gene set. hyperGTest produced a set of predicted
gene annotations Np for each p [ P based on the annotation of
neighbors Q. We applied Bonferroni correction to the p-values
associated with each prediction by multiplying each p-value by the
total number of predictions made for the corresponding probeset.
We used these corrected p-values from predicted annotations Np
that were known to be non-computationally assigned from the
hgu133plus package of Bioconductor [36] to establish a conserva-
tive cutoff, below which predicted annotations should all be high
quality.
Analyzing Linkage Regions
For a given phenotype, a group of known genes G for which
mutations have been described that lead to a specific phenotype
were retrieved from previous publications and online databases.
The list of genes was transformed to a list of probesets P present on
the HG-U133_Plus_2 array design using the gene symbol ?
probeset mapping available from NetAffx [34]. All disease causing
probesets P mapped to a unique location in the genome within a
6 Mb interval termed A around the known causative gene were
identified by finding the center point of each probeset’s alignment
to UCSC March 2006 (hg18) version of the human genome [25].
Each region in A was then mapped to a list of all HG-
U133_Plus_2 probesets Q aligned to that region. Then, for each
p [ P, a QxG(GEg)lab was retrieved from C’’ (Section 3.1.3), and
row-summarized to produce a Q-length vector
?  r r of mean
correlation coefficients to G ] g.
Analysis of Human Disease Genes
Genes for LGMD2, Joubert Syndrome, and Microcephaly were
selected based on literature search/OMIM classifications as of
September 2008. Disorder-gene mapping relied on affiliation [61].
All genes identified as causing 43 disorders, were first mapped to
the Affymetrix U133_2.0 array to determine if a probeset existed
for each gene. All probesets mapping to each gene were retrieved
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correlation coefficients within a disorder causing gene list were
calculated as described above except that for genes with multiple
probesets, the correlation coefficients between the probesets of the
same gene were excluded. We name them Intra-disorder
correlation. As a general rule of thumb, probes with a mean
Intra-disorder correlation $0.1 are considered nominally corre-
lated. Gene-gene correlation coefficients between this gene list and
all other genes in U133_2.0 arrays were also calculated. We name
them Extra-disorder correlation. A two sample t-test was then
performed comparing these two groups of correlation coefficients.
qRT-PCR
One microgram of RNA from seven tissues (adipose, brain,
kidney, ovary, heart, small intestine, and liver) in the FirstChoiceH
Human Total RNA survey panel (Ambion) was reverse tran-
scribed using a high-capacity cDNA archive kit (ABI) and random
primers. For cartilage, RNA from three independent cartilage
samples was pooled and reverse transcribed. Amplification
reactions were performed in duplicate using 50 ng of each cDNA.
Thirty-five cycles of amplification were carried out in an ABI 7300
using the validated QuantiTect Gene Expression Assays and
SYBR Green PCR kit (Qiagen). To assess specificity, amplification
products were subjected to melting curve analysis and gel
electrophoresis. The 2- [delta] [delta]Ct method was employed
to calculate relative amplification. This was performed using an
average of endogenous references (18S, GAPDH, and HPRT1)t o
improve normalization across the panel of tissues used. For genes
where no amplification was detected in a tissue, a Ct value of 35
was assigned, reflecting the maximum number of cycles carried
out.
Supporting Information
Table S1 Representative genes are listed in rank order of mean
similarity to the human cartilage-selective seeding profile identified
in Figure 1 and represented in Column 1. Column 6 identifies
genes, labeled with an X, which can result in skeletal abnormalities
in humans [32]. Column 7 identifies associated mouse phenotypes
summarized from Mouse Genome Database [33] (‘‘N/A’’
indicates targeted model not available; ‘‘-’’ targeted mouse model
has no skeletal phenotype yet). Column 8 indicates genes that were
similarly identified in the mouse from Affy 430 2.0 whole genome
array data as being in the top 100 cartilage selective genes.
Column 8 indicates genes which are previously identified in Funari
et al., 2007 et. al. as cartilage-selective. Column 9 indicates genes
identified in Funari et al., 2007 as enriched in cartilage using data
from the U133 2.0 platform and the first 200 ranked genes with a
false discovery rate of zero using Significance of Microarray (SAM)
analysis.
Found at: doi:10.1371/journal.pone.0008491.s001 (0.04 MB
XLS)
Table S2 To identify an autism-related expression model, the 26
genes identified as ‘‘probable’’ or ‘‘promising’’ in a recent review
of autism genetics were used as both ‘training’ and ‘test’ sets in
UGET. An expression module of 25 probes representing 13 genes
(listed in this table) was identified as both highly inter-correlated
and highly correlated to the total list of 26 ‘‘probable’’ or
‘‘promising’’ autism genes, and is thus deemed ‘autism-related.’
This module was used as a training set to assess the mean co-
expression correlation between the module and all 54,613 probes
on the Affymetrix U133A_2.0 Human Gene Expression Micro-
array. The most highly correlated probe mapping to a given gene
was selected as representative for that gene.
Found at: doi:10.1371/journal.pone.0008491.s002 (0.04 MB
DOC)
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